VBL falls on Phase III glioblastoma miss

Vascular Biogenics Ltd. (NASDAQ:VBLT) was off $4.15 (61%) to $2.65 on Thursday, losing over $120 million in market cap, after reporting that ofranergene obadenovec (VB-111) missed the

Read the full 271 word article

User Sign In